A rapid and systematic review of the clinical effectiveness and cost effectiveness of pegylated liposomal doxorubicin hydrochloride (Caelyx UK, Doxil, USA) for ovarian cancer

C. Forbes; J. Wilby; G. Richardson; L. Mather; M. Sculpher; R. Riemsma

A rapid and systematic review of the clinical effectiveness and cost effectiveness of pegylated liposomal doxorubicin hydrochloride (Caelyx UK, Doxil, USA) for ovarian cancer

C. Forbes, J. Wilby, G. Richardson, L. Mather, M. Sculpher, R. Riemsma

Centre for Health Economics

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	1-119
Number of pages	119
Journal	Health technology assessment
Volume	6
Issue number	23
Publication status	Published - 2002

Cite this

@article{7e73e5674d6b450a80b036c688530305,

title = "A rapid and systematic review of the clinical effectiveness and cost effectiveness of pegylated liposomal doxorubicin hydrochloride (Caelyx UK, Doxil, USA) for ovarian cancer",

author = "C. Forbes and J. Wilby and G. Richardson and L. Mather and M. Sculpher and R. Riemsma",

year = "2002",

language = "English",

volume = "6",

pages = "1--119",

journal = "Health technology assessment",

issn = "2046-4924",

publisher = "NHS National Institute for Health Research",

number = "23",

}

TY - JOUR

T1 - A rapid and systematic review of the clinical effectiveness and cost effectiveness of pegylated liposomal doxorubicin hydrochloride (Caelyx UK, Doxil, USA) for ovarian cancer

AU - Forbes, C.

AU - Wilby, J.

AU - Richardson, G.

AU - Mather, L.

AU - Sculpher, M.

AU - Riemsma, R.

PY - 2002

Y1 - 2002

M3 - Article

SN - 2046-4924

VL - 6

SP - 1

EP - 119

JO - Health technology assessment

JF - Health technology assessment

IS - 23

ER -